Login to Your Account



PharmaFocus

MD Anderson, GSK Ink Potential $335M Oncology Drug Pact

By Marie Powers
Staff Writer

Monday, December 10, 2012
The University of Texas MD Anderson Cancer Center has emerged as one of the hot spots in the U.S. for cancer research, and GlaxoSmithKline (GSK) plc pounced on that potential with a research collaboration and license agreement for cancer immunotherapeutic antibodies that is structured more like a standard biotech deal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription